Sezgin, CanfezaÖzdemir, NecmettinGöker, Erdem2022-10-252022-10-252007-01Sezgin, C. vd. (2007). "Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome". Southern Medical Journal, 100(1), 27-32.0038-43481541-8243https://doi.org/10.1097/01.smj.0000252968.87824.19https://sma.org/southern-medical-journal/article/efficacy-of-lower-dose-capecitabine-in-patients-with-metastatic-breast-cancer-and-factors-influencing-therapeutic-response-and-outcome/http://hdl.handle.net/11452/29196Objective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.eninfo:eu-repo/semantics/closedAccessGeneral & internal medicineCapecitabineMetastatic breast cancerMulticenter Phase IICarcinomaAmplificationSafetyDeoxycytidineAdministration, oralAdultAgedAntimetabolites, antineoplasticBreast neoplasmsDisease progressionNeoplasm metastasisFollow-up studiesRetrospective studiesDose-response relationship, drugFemaleFluorouracilHumansMiddle agedProdrugsSurvival rateTreatment outcomeArticle0002467773000092-s2.0-338462470782732100117269522Medicine, general & internalCapecitabine; Hand Foot Syndrome; Vinorelbine TartrateTamoxifenAnthracyclineCapecitabineCyclophosphamideFluorouracilMethotrexateConjunctivitisTaxane derivativeAdultAgedAnemiaAnorexiaAntineoplastic activityArticleBreast cancerCancer chemotherapyHumanDiarrheaDrug efficacyDrug responseDrug safetyDyspepsiaFatigueHand foot syndromeNauseaMultivariate analysisInfectionMajor clinical studySide effectToxic hepatitisTreatment outcomeUnivariate analysis